ÃĪ«¤Þ°_ªº¦åºÞ©Ê¤ô¸~
![]() |
| ¦åºÞ©Ê¤ô¸~ (angioedema)
¥i¥HÅý§A¤@¬íÅÜÁy¡A¦åºÞ©Ê¤ô¸~¬O¤@ºØ¬ðµo©Êªº²`³¡¥Ö½§©ÎÂH½¤¤ô¸~¡C ÅU¦W«ä¸q¡A¦åºÞ³q³z«×¤j´T¼W¥[¡AÅý²GÅé±q¦åºÞº¯³z¨ì²Õ´¤º¡A§Y³y¦¨¤ô¸~¡C ³y¦¨¦åºÞ©Ê¤ô¸~ªºì¦]«Ü¦h¡A¥]¬A·P¬V¡B¹ª«¡BÃĪ«µ¥µ¥¡A³q±`±N¦åºÞ©Ê¤ô¸~®Ú¾Ú¯f¦]¾Ç¤À¦¨¡G (1) ¥¨²ÓM¬¡¤Æ«¬ (mast cells activation)¡G¥]¬A¹L±Ó¤ÏÀ³¡A¨Ò¦pIgE¬ÛÃöªº¹L±Ó¤ÏÀ³¡Bª½±µ¨ë¿E¥¨²ÓM¡BNSAIDs©ÎAspirinµ¥µ¥¡C (2) ½w°Ê¯À¥Í¦¨«¬ (generation of bradykinin)¡G³ÌµÛ¦Wªº´N¬O°¦åÀ£ÃÄ«~ACEI¤Þ°_ªº¦åºÞ©Ê¤ô¸~¡A¥t¤@Ó´¿¸g³Q´£¨ìªº¬O¤fªA°¦å¿}ÃÄ«~DPP-§í¨î¾¯¡C (3) ¾÷Âॼ©ú«¬ (unknown mechanisms)¡G¨Ò¦p·P¬V¡B¶tÂ÷¤lªýÂ_¾¯©Î¨ä¥LÃÄ«~¤Þ°_ªº¡A¬Æ¦Ü¬O¶Ý¥ì¬õ©Ê²y¹L¦h¯gÔ¸s (Hypereosinophilic syndrome) µ¥µ¥¡C ÈÐACEI¤Þ°_ªº¦åºÞ©Ê¤ô¸~³Ì¬°¨å«¬ÈÐ ACEI (¦åºÞ±i¤O¯ÀÂà¤Æ–¡§í¨î¾¯)¡A¦]¬°¾÷Â઺Ãö«Y¡A§í¨î¦åºÞ±i¤O¯ÀÂà¤Æ–¡¡A·|´î¤Ö½w°Ê¯À (bradykinin) ³Q¤À¸Ñ¡A¦]¦¹¼W¥[½w°Ê¯À¡C ¦Ó½w°Ê¯À·|³y¦¨¦åºÞÂX±i¡B¼W¥[¦åºÞ³q³z«×¡A¦]¦¹¾ÉP¦åºÞ¤ô¸~¡C½Ðª`·N¡A³oÃþ¾÷Âà¨Ã«DÈйL±Ó¤ÏÀ³ÈСA§ó¦h®ÉÔ¤Þ°_ªº¬OÈиzG¹DÂH½¤¤ô¸~ÈСA¾ÉP¸¡µh¡Bäú¤ß¡B¹Ã¦R¡B¸¡Âm¡C ÈЦ]¬°¸zG¹D¯gª¬»P³oÃþÃÄ«~ªº¾÷Âण·f¹Ç¡A©Ò¥H«D±`®e©ö»~¶E©Îº|±¼¡A½Ð¯S§O¤p¤ß¡CÈÐ ½w°Ê¯À¤Þ°_ªº¦åºÞ¤ô¸~¡A¦]¬°»P²Õ´ÓiµLÃö¡A¨Ï¥Î§Ü²Õ´ÓiÃÄ«~¡BµÇ¤W¸¢¯À©ÎÃþ©T¾J¬OÈеL®ÄªºÈСC ÁöµM¦³°w¹ï½w°Ê¯À¾÷Â઺·sÃÄ (icatibant¡Becallantide) ¥iªvÀøACEI¤Þ°_ªº¦åºÞ¤ô¸~¡A¦ý¥Ø«e¨S¿ìªk¨ú±o¡A¤]¬OªPµM¡C °£¤F°±ÃÄ (°±¤îACEIªvÀø)¡B°µ¸Ó°µªº (ºZ³q©I§l¹D»P¨ä¥L¤ä«ù©ÊÀøªk)¡B®³¤£¨ìªº·sÃÄ¥~¡A´¿¦³¯f¨Ò³ø§i¨Ï¥ÎÈзsÂA§Ná¦å¼ß (FFP)ÈЪvÀøACEI¤Þ°_ªº¦åºÞ¤ô¸~¡A¦]¬°FFP¤¤¥]¬AACE³oӻïÀ¡A¦b¯f¨Ò³ø§i¤¤¡A¥i§Ö³t§ïµ½¦åºÞ¤ô¸~¯gª¬¡C °£¤FACEI¥~¡A¨ä¥L¥]¬AAspirin¡BNSAID¡B¶tÂ÷¤lªýÂ_¾¯µ¥¡A¦b¯f¨Ò³ø§i¤¤³£³Q³ø§i¥i¯à¤Þ°_¦åºÞ¤ô¸~¡C |